Prospective randomized trial of everolimus- and zotarolimus-eluting stents for treatment of unprotected left main coronary artery disease: ISAR-LEFT-MAIN-2.

Trial Profile

Prospective randomized trial of everolimus- and zotarolimus-eluting stents for treatment of unprotected left main coronary artery disease: ISAR-LEFT-MAIN-2.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Everolimus (Primary) ; Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms ISAR-LEFT-MAIN-2
  • Most Recent Events

    • 08 Aug 2013 Primary endpoint 'Major-adverse-cardiac-event-rate' has not been met according to results published in the Journal of the American College of Cardiology.
    • 08 Aug 2013 Results published in the Journal of the American College of Cardiology.
    • 04 Jan 2012 Additional lead trial investigator identified and actual patient number is 650 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top